Expert Review of Hematology · 2020 · 43 citations · 23 references
MedicinePharmacologyPharmacotherapyClinical EpidemiologyComparative Effectiveness ResearchImmunotherapyClinical TrialsFrailty AssessmentHematologic Malignancy TherapyMultiple MyelomaCytogenetic AbnormalitiesCytogenetic Risk StratificationMultiple Myeloma TherapyMultiple Myeloma TreatmentProteasome Inhibitor TherapyProteasome InhibitorsRefractory Multiple MyelomaRelapsed Multiple Myeloma
score of intermediate/frail; 20%/28%/13% had high cytogenetic risk in I-/K-/V-Rd groups. Risk of PI-triplet discontinuation was lower for I- vs. K-Rd (HR: 0.71) and I- vs. V-Rd (HR: 0.85); unadjusted, median TTNTs (months): 12.7/8.6/14.2 (LOT ≥2) and 16.8/9.5/14.6 (LOT 2-3) (I-/K-/V-Rd). Adjusted TTNT was comparable between I-/K-/V-Rd in LOT ≥2 with a TTNT benefit among intermediate/frail patients for I- (HR: 0.70; P=0.04) and V- (HR: 0.73; P<0.05) vs. K-Rd. I/K/V-Rd triplets were comparable in TTNT overall, but IRd and VRd were associated with longer TTNT in intermediate/frail patients than KRd. The results suggest a trial-efficacy/real-world-effectiveness gap, especially for KRd, underlining the limited generalizability of trial results where >50% of patients are excluded. Individualized treatment based on patient characteristics, such as frailty status, is especially pertinent in an elderly RRMM population.
23
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood · 2007 · 2.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text